HomeCompareBNOEF vs O

BNOEF vs O: Dividend Comparison 2026

BNOEF yields 33333.33% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNOEF wins by $8.428195308647591e+21M in total portfolio value
10 years
BNOEF
BNOEF
● Live price
33333.33%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.428195308647591e+21M
Annual income
$8,378,748,509,141,157,000,000,000,000.00
Full BNOEF calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — BNOEF vs O

📍 BNOEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNOEFO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNOEF + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BNOEF pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNOEF
Annual income on $10K today (after 15% tax)
$2,833,333.33/yr
After 10yr DRIP, annual income (after tax)
$7,121,936,232,769,983,000,000,000,000.00/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, BNOEF beats the other by $7,121,936,232,769,983,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNOEF + O for your $10,000?

BNOEF: 50%O: 50%
100% O50/50100% BNOEF
Portfolio after 10yr
$4.2140976543237957e+21M
Annual income
$4,189,374,254,570,578,700,000,000,000.00/yr
Blended yield
99.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

BNOEF
No analyst data
Altman Z
-5.0
Piotroski
6/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNOEF buys
0
O buys
0
No recent congressional trades found for BNOEF or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNOEFO
Forward yield33333.33%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$8.428195308647591e+21M$34.2K
Annual income after 10y$8,378,748,509,141,157,000,000,000,000.00$5,102.74
Total dividends collected$8.424943808765552e+21M$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: BNOEF vs O ($10,000, DRIP)

YearBNOEF PortfolioBNOEF Income/yrO PortfolioO Income/yrGap
1← crossover$3,344,033$3,333,333.33$10,818$608.16+$3.33MBNOEF
2$1,045,333,048$1,041,754,932.50$11,787$741.68+$1045.32MBNOEF
3$305,463,295,767$304,344,789,404.97$12,946$911.00+$305463.28MBNOEF
4$83,443,192,327,233$83,116,346,600,762.75$14,345$1,127.94+$83443192.31MBNOEF
5$21,308,754,850,592,396$21,219,470,634,802,260.00$16,056$1,409.05+$21308754850.58MBNOEF
6$5,087,082,937,849,453,000$5,064,282,570,159,319,000.00$18,171$1,777.83+$5087082937849.43MBNOEF
7$1,135,355,897,925,379,400,000$1,129,912,719,181,880,500,000.00$20,820$2,268.21+$1135355897925379.50MBNOEF
8$236,895,694,937,506,160,000,000$235,680,864,126,726,020,000,000.00$24,188$2,929.90+$236895694937506176.00MBNOEF
9$46,211,962,155,546,610,000,000,000$45,958,483,761,963,480,000,000,000.00$28,533$3,837.11+$46211962155546607616.00MBNOEF
10$8,428,195,308,647,591,000,000,000,000$8,378,748,509,141,157,000,000,000,000.00$34,235$5,102.74+$8.428195308647591e+21MBNOEF

BNOEF vs O: Complete Analysis 2026

BNOEFStock

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Full BNOEF Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this BNOEF vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNOEF vs SCHDBNOEF vs JEPIBNOEF vs KOBNOEF vs MAINBNOEF vs STAGBNOEF vs ADCBNOEF vs NNNBNOEF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.